ALPMY (Astellas Pharma) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALPMY Astellas Pharma Inc ALPMY
80 GF Score
Price $15.18
GF Value $14.34
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Astellas Pharma  (OTCPK:ALPMY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Astellas Pharma Cyclically Adjusted PB Ratio Related Terms


Astellas Pharma Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Cyclically Adjusted PB Ratio Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.59 2.27 1.69 1.46 2.41

Astellas Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.46 1.63 1.97 2.40 1.96

ALPMY vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted PB Ratio falls into.


ALPMY
80GF Score
Astellas Pharma Inc ALPMY
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Astellas Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Astellas Pharma's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.673/113.6000*113.6000
=6.673

Current CPI (Jun. 2026) = 113.6000.

Astellas Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201609 5.704 98.000 6.612
201612 5.376 98.400 6.206
201703 5.527 98.100 6.400
201706 5.688 98.500 6.560
201709 5.914 98.800 6.800
201712 6.020 99.400 6.880
201803 6.035 99.200 6.911
201806 5.876 99.200 6.729
201809 5.879 99.900 6.685
201812 6.131 99.700 6.986
201903 6.029 99.700 6.870
201906 6.150 99.800 7.000
201909 6.361 100.100 7.219
201912 6.499 100.500 7.346
202003 6.429 100.300 7.281
202006 6.521 99.900 7.415
202009 6.783 99.900 7.713
202012 7.136 99.300 8.164
202103 6.769 99.900 7.697
202106 6.724 99.500 7.677
202109 6.857 100.100 7.782
202112 6.872 100.100 7.799
202203 6.585 101.100 7.399
202206 6.216 101.800 6.937
202209 6.253 103.100 6.890
202212 6.530 104.100 7.126
202303 6.306 104.400 6.862
202306 6.091 105.200 6.577
202309 6.127 106.200 6.554
202312 5.947 106.800 6.326
202403 5.881 107.200 6.232
202406 5.823 108.200 6.114
202409 5.975 108.900 6.233
202412 5.310 110.700 5.449
202503 5.652 111.100 5.779
202506 5.727 111.700 5.824
202509 6.095 112.000 6.182
202512 6.285 113.000 6.318
202603 6.424 112.700 6.475
202606 6.673 113.600 6.673

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Astellas Pharma (ALPMY) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued. The current stock price of $15.18 is trading 5.9% above its estimated GF Value™ of $14.34. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMY:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $14.34 vs. price of $15.18 (5.9% above fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the ALPMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
80GF Score

Get the complete analysis for ALPMY

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.18
Price
$14.34
GF Value